206 related articles for article (PubMed ID: 19483104)
1. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Walker T; Mitchell C; Park MA; Yacoub A; Graf M; Rahmani M; Houghton PJ; Voelkel-Johnson C; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):342-55. PubMed ID: 19483104
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Park MA; Zhang G; Martin AP; Hamed H; Mitchell C; Hylemon PB; Graf M; Rahmani M; Ryan K; Liu X; Spiegel S; Norris J; Fisher PB; Grant S; Dent P
Cancer Biol Ther; 2008 Oct; 7(10):1648-62. PubMed ID: 18787411
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Park MA; Reinehr R; Häussinger D; Voelkel-Johnson C; Ogretmen B; Yacoub A; Grant S; Dent P
Mol Cancer Ther; 2010 Aug; 9(8):2220-31. PubMed ID: 20682655
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Park MA; Mitchell C; Zhang G; Yacoub A; Allegood J; Häussinger D; Reinehr R; Larner A; Spiegel S; Fisher PB; Voelkel-Johnson C; Ogretmen B; Grant S; Dent P
Cancer Res; 2010 Aug; 70(15):6313-24. PubMed ID: 20631069
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Park MA; Zhang G; Mitchell C; Rahmani M; Hamed H; Hagan MP; Yacoub A; Curiel DT; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2008 Sep; 7(9):2633-48. PubMed ID: 18790746
[TBL] [Abstract][Full Text] [Related]
12. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Bareford MD; Hamed HA; Allegood J; Cruickshanks N; Poklepovic A; Park MA; Ogretmen B; Spiegel S; Grant S; Dent P
Cancer Biol Ther; 2012 Jul; 13(9):793-803. PubMed ID: 22673740
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Tang Y; Yacoub A; Hamed HA; Poklepovic A; Tye G; Grant S; Dent P
Cancer Biol Ther; 2012 May; 13(7):567-74. PubMed ID: 22406992
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Sajithlal GB; Hamed HA; Cruickshanks N; Booth L; Tavallai S; Syed J; Grant S; Poklepovic A; Dent P
Mol Pharmacol; 2013 Oct; 84(4):562-71. PubMed ID: 23877009
[TBL] [Abstract][Full Text] [Related]
16. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
17. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Walker T; Mitchell C; Park MA; Yacoub A; Rahmani M; Häussinger D; Reinehr R; Voelkel-Johnson C; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2010 May; 9(5):1378-95. PubMed ID: 20442308
[TBL] [Abstract][Full Text] [Related]
18. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.
Park MA; Walker T; Martin AP; Allegood J; Vozhilla N; Emdad L; Sarkar D; Rahmani M; Graf M; Yacoub A; Koumenis C; Spiegel S; Curiel DT; Voelkel-Johnson C; Grant S; Fisher PB; Dent P
Mol Cancer Ther; 2009 May; 8(5):1280-91. PubMed ID: 19417161
[TBL] [Abstract][Full Text] [Related]
19. Regulation of autophagy by ceramide-CD95-PERK signaling.
Park MA; Zhang G; Norris J; Hylemon PB; Fisher PB; Grant S; Dent P
Autophagy; 2008 Oct; 4(7):929-31. PubMed ID: 18719356
[TBL] [Abstract][Full Text] [Related]
20. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
